Sri Yudah

Ms. Sri Yudah

Optometry, Singapore National Eye Center, Singapore, Central Singapore, Singapore

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
KLKai-lyn Loh
Kai-lyn Loh
PCPauline Poh Lin Chan
Pauline Poh Lin Chan
SYSri Yudah
Sri Yudah
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
Objectives: To evaluate the 24-month efficacy of combining highly aspherical lenslet target (HALT) spectacle lenses with low-dose atropine (LDA) in children with poor response to atropine monotherapy. Methods: This prospective interventional cohort study included myopic children aged 6–11 years who continued to progress despite LDA (0.01–0.025%). Fifty children completed 12 months of follow-up and 48 completed 24 months. At 12 months, atropine dosage was maintained, reduced, or increased according to clinical discretion. Cycloplegic spherical equivalent refraction (SER) and axial length (AL) were measured at baseline, 12 months, and 24 months. Results: Myopia progression during the first year (SER: −0.07 ± 0.45 D; AL: 0.13 ± 0.14 mm) was markedly lower than during the 6 months before treatment (SER: −0.61 ± 0.39 D; AL: 0.24 ± 0.12 mm). During the second year, atropine dosage was reduced in 23%, maintained in 67%, and increased in 10% of participants. Mean second-year progression was −0.26 ± 0.41 D and 0.17 ± 0.17 mm, with no significant differences between treatment groups. Although second-year SER progression exceeded first-year progression (p = 0.003), both SER and AL progression remained significantly lower than pre-treatment rates (p = 0.004). Over 24 months, 73.9% of eyes progressed ≤ 0.50 D and 71.7% progressed ≤ 0.40 mm. Younger age and greater first-year progression independently predicted greater 24-month SER and AL progression. Conclusions: Myopia progression was relatively well sustained over 24 months after combination treatment was started in children previously progressing on LDA. Younger children and those with greater early progression may warrant closer monitoring.

4 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NKNg Kaiwen
Ng Kaiwen
AGAaron Qi Yang Goh
Aaron Qi Yang Goh
BSBryan Xiangrong Sim
Bryan Xiangrong Sim
SYSri Yudah
Sri Yudah
PCPauline Poh Lin Chan
Pauline Poh Lin Chan
ACAudrey Wei Lin Chia
Audrey Wei Lin Chia
Aim: In this retrospective audit, Atropine 0.025% eyedrops were evaluated in a clinical setting. Method: Children aged 4–16 years, who were started on Atropine 0.025% with at least 6 months of follow-up, were included. A total of 588 eyes (299 children) were classified as treatment-naïve eyes started on Atropine 0.025% daily (Group A, n146), eyes progressing on Atropine 0.01% daily increased to 0.025% daily (Group B, n287) or combined with myopia control glasses (Group C, n66), and those stable on Atropine 0.01% twice daily converted to Atropine 0.025% daily (Group D, n89). Spherical equivalent (SE) and axial length (AL) were recorded from 6 months before treatment to 24 months after treatment began. Result: Group A children were younger (8.4 ± 1.5 years), while Group D children were older (10.6 ± 1.59 years). Progression in the first 6 m was significantly less than that in 6 m prior in Groups A-C. At 1 year, a change in AL < 0.15 mm was noted in 41%, 49%, 50% and 35%, and a change in AL ≥ 0.30 mm was observed in 38%, 18%, 32% and 23% of eyes in Groups A, B, C and D, respectively. Treatment was increased in 37%, 34%, 12% and 41% of eyes over 2 years in Groups A, B, C and D, respectively. Mean progression at 2 years was −0.63 ± 0.86 D or 0.44 ± 0.31 mm, −0.39 ± 0.59 D or 0.30 ± 0.26 mm, −0.30 ± 0.48 D or 0.36 ± 0.40 mm, and −0.48 ± 0.54 D or 0.33 ± 0.22 mm in Groups A, B, C and D, respectively. Multivariate analysis suggested that progression was mainly associated with younger age. Conclusions: Atropine 0.025% was a useful addition to myopia control, with some eyes requiring further modification in treatment.